*The following content is generated by AI and is for reference only.
Cabazitaxel is a novel third-generation taxane chemotherapy agent, chemically distinct from its predecessors paclitaxel and docetaxel. Its molecular formula is C43H53NO14, with a precise CAS number of 208976-53-8. Structurally, it features a unique side chain at the C10 position and an additional hydroxyl group at C2 compared to docetaxel. This specific modification enhances its lipophilicity and binding affinity to tubulin, allowing it to effectively stabilize microtubules and inhibit their depolymerization even in cells that have developed resistance to other taxanes.
The primary clinical indication for Cabazitaxel is the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is specifically approved for patients whose disease has progressed following prior androgen deprivation therapy and after receiving a docetaxel-based regimen. In this setting, Cabazitaxel is typically administered intravenously in combination with prednisone or prednisolone. Clinical trials have demonstrated that adding Cabazitaxel significantly improves overall survival and delays disease progression compared to switching to mitoxantrone plus prednisone in heavily pretreated patients. The drug works by disrupting the dynamic instability of microtubules, which are essential for cell division, thereby arresting the cell cycle in the G2/M phase and inducing apoptosis in rapidly dividing cancer cells.
While highly effective, Cabazitaxel carries a significant safety profile similar to other taxanes but with a notably higher incidence of neutropenia and diarrhea. Consequently, dose adjustments and growth factor support are often required during treatment cycles. Patients must be closely monitored for hypersensitivity reactions, although premedication protocols help mitigate these risks. Beyond prostate cancer, ongoing research explores its potential efficacy in other solid tumors, including breast and lung cancers, though it remains most established in the mCRPC landscape. As a potent cytotoxic agent, Cabazitaxel represents a crucial therapeutic option for extending life and maintaining quality of life in men with advanced prostate cancer who have exhausted standard first-line taxane therapies. Its development marked a significant advancement in overcoming multidrug resistance mechanisms inherent in tumor cells.